Coherus BioSciences, Inc. Stock

$0.75

7.88%

Nasdaq, Jul 07, 10:00 pm CET

ISIN

US19249H1032

Symbol

CHRS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Coherus BioSciences, Inc. Stock price

$0.75

-17.14 95.83% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.06 7.88%

ISIN

US19249H1032

Symbol

CHRS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$93.9m

Enterprise Value

$306.4m

Net debt

$212.5m

Cash

$82.4m

Shares outstanding

115.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.5 | 1.6

EV/Sales

1.6 | 5.4

EV/FCF

612.8

P/B

negative

Financial Health

Equity Ratio

-29.4%

Return on Equity

-21.6%

ROCE

-89.9%

ROIC

-47.1%

Debt/Equity

-1.6

Financials (TTM | estimate)

Revenue

$197.5m | $57.2m

EBITDA

$-99.5m | $-169.8m

EBIT

$-104.3m | $-187.3m

Net Income

$-130.9m | $-135.6m

Free Cash Flow

$500.0k

Growth (TTM | estimate)

Revenue

-34.6% | -78.6%

EBITDA

39.0% | -82.8%

EBIT

37.7% | -

Net Income

-120.9% | -575.5%

Free Cash Flow

100.3%

EPS

$-1.1

FCF per Share

$0.0

Short interest

28.7%

Employees

228

Rev per Employee

$1.2m

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Coherus BioSciences, Inc. Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Coherus BioSciences, Inc. forecast:

9x Buy

69%

4x Hold

31%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Coherus BioSciences, Inc. forecast:

Buy

69%

Hold

31%

Analyst Estimates with Stock Price Targets

Financial data from Coherus BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	198 198	35% 35% 100%
- Direct Costs	86 86	52% 52% 43%
Gross Profit	112 112	11% 11% 57%
- Selling and Administrative Expenses	131 131	31% 31% 66%
- Research and Development Expense	89 89	14% 14% 45%
EBITDA	-99 -99	39% 39% -50%
- Depreciation and Amortization	4.82 4.82	10% 10% 2%
EBIT (Operating Income) EBIT	-104 -104	38% 38% -53%
Net Profit	-131 -131	121% 121% -66%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Coherus BioSciences, Inc. Stock News

Neutral

Seeking Alpha

●

about 2 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Confere...

Neutral

GlobeNewsWire

●

about 2 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizu...

Neutral

GlobeNewsWire

●

2 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business...

More Coherus BioSciences, Inc. News

Company Profile

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Denny Lanfear
Employees	228
Founded	2010
Website	www.coherus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now